It is Canadian real-world evidence data in our patients treated with the belumosudil for steroid refractory chronic GVHD. We have a look at the treatment outcome of belumosudil treatment, which has been approved by Health Canada and the US FDA for the treatment of later-line chronic GvHD therapy in patients who failed more than two lines of treatment.
Out of the 36 patients, their response rate was very replicable in comparison to the previous data, which showed around 55 to 60 percent of response rate...
It is Canadian real-world evidence data in our patients treated with the belumosudil for steroid refractory chronic GVHD. We have a look at the treatment outcome of belumosudil treatment, which has been approved by Health Canada and the US FDA for the treatment of later-line chronic GvHD therapy in patients who failed more than two lines of treatment.
Out of the 36 patients, their response rate was very replicable in comparison to the previous data, which showed around 55 to 60 percent of response rate. On top of that, we have looked at their modified Lee symptom score in patients at 3, 6, 12, and further on. The best clinically meaningful improvement of their modified Lee symptom score, it was observed in roughly around two-thirds of the patients. So I would like to emphasize that they are gaining a definite benefit from the belumosudil treatment, and when you follow them longitudinally, we can continue to see that kind of improvement in our patients. That is our main message for that study.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
